EMA Recommends First Gene Therapy for Wiskott-Aldrich Syndrome
Key Insights
The European Medicines Agency (search) has recommended marketing authorization for Waskyra (search) (etuvetidigene autotemcel (search)), the first gene therapy to treat Wiskott-Aldrich syndrome (search) in patients aged 6 months and older.
Clinical data from 27 patients showed dramatic reductions in severe infections from 2.0 events annually before treatment to 0.12 events in the 2-3 years post-treatment.
The therapy addresses a critical unmet medical need for patients requiring stem cell transplantation but lacking suitable donors for this rare inherited disorder.
The European Medicines Agency (search) (EMA) has recommended granting marketing authorization for Waskyra (search) (etuvetidigene autotemcel (search)), marking a significant milestone as the first gene therapy approved to treat Wiskott-Aldrich syndrome (search) (WAS). The therapy is indicated for patients aged 6 months and older who have a mutation in the WAS gene and require hematopoietic stem cell transplantation but lack a suitable donor.
Addressing a Critical Unmet Medical Need
Wiskott-Aldrich syndrome (search) is a rare, inherited disease affecting almost exclusively males, characterized by abnormalities in blood cells and immune system function. The condition results from mutations in the gene that produces the WAS protein (search), essential for normal development and function of blood cells and certain immune cells.
Patients with WAS face multiple life-threatening complications. They bruise and bleed easily due to insufficient normal platelets, experience frequent infections from inadequate immune cells that can lead to sepsis (search), and have an elevated risk of developing cancers such as lymphoma (search). While patients with compatible donors can receive hematopoietic stem cell transplantation, most patients lack suitable donors, creating a significant treatment gap.
Revolutionary Gene Therapy Approach
Waskyra (search) represents an innovative autologous gene therapy solution. The treatment involves collecting CD34+ stem cells from the patient's blood, genetically modifying them in the laboratory to produce functional WAS protein (search), and reinfusing them after a conditioning regimen. The modified cells migrate to the bone marrow, where they generate healthy blood and immune cells capable of producing functional WAS protein, thereby addressing the underlying cause of the disease symptoms.
The therapy is administered as a single intravenous infusion, offering a potentially curative treatment option for patients who previously had limited therapeutic alternatives.
Compelling Clinical Evidence
EMA's recommendation is based on comprehensive data from a clinical development program involving 27 patients with Wiskott-Aldrich syndrome (search). The primary evidence came from a single-arm clinical trial conducted in 10 children aged 1 to 9 years, supplemented by data from another clinical trial and an expanded access program including 17 patients aged 1 to 35 years.
The clinical results demonstrated remarkable efficacy improvements. The annualized rate of severe infections decreased dramatically from 2.0 events in the 12 months before treatment to 0.15 events in the 1-2 years post-Waskyra (search) administration, and further to 0.12 events in the 2-3 years post-treatment period. Similarly, moderate and severe bleeding episodes showed substantial reduction from 2.0 events annually before treatment to 0.16 events in the 2-3 years following Waskyra administration.
Safety Profile and Regulatory Assessment
The most commonly reported side effects were associated with the procedures and medications required for treatment administration, including the conditioning regimen, pre-treatment protocols, and administration site conditions such as infusion device-related infections and catheter site bleeding.
The Committee for Advanced Therapies (CAT), EMA's expert committee for cell- and gene-based medicines, concluded that Waskyra (search)'s benefits outweighed the potential risks for patients with Wiskott-Aldrich syndrome (search) requiring HSCT but lacking suitable donors. The Committee for Medicinal Products for Human Use (CHMP) concurred with this assessment and recommended approval.
Enhanced Regulatory Support
Waskyra (search) benefited from EMA's pilot program offering enhanced support to academic and non-profit developers of advanced therapy medicinal products addressing unmet medical needs. This ongoing pilot program, which includes two other medicines under development, provides enhanced EMA support for navigating EU regulatory requirements and offers fee incentives for scientific advice, marketing authorization applications, and pre-authorization inspections.
The CHMP opinion represents an intermediary step toward patient access. The recommendation will now proceed to the European Commission for final decision on EU-wide marketing authorization. Following approval, individual Member States will make pricing and reimbursement decisions considering the therapy's role within their respective national health systems.